文献速递肥胖与代谢综合征

功能障碍性脂肪组织中维生素D释放受损:肥胖症维生素D补充的新线索

Impaired Release of Vitamin D in Dysfunctional Adipose Tissue: New Cues on Vitamin D Supplementation in Obesity.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究纳入54名正常体重和67名肥胖男性,随机接受每周50微克25-羟基维生素D3或150微克维生素D3补充1年,97人完成。功能障碍脂肪组织儿茶酚胺诱导的维生素D3和25-羟基维生素D3释放减少,且25-羟基维生素D3补充在肥胖者中更有效达到维生素D充足。

要点

  • 胰岛素抵抗脂肪细胞和肥胖者皮下脂肪组织中肾上腺素诱导的维生素D3和25-羟基维生素D3释放受损。
  • 肥胖者补充25-羟基维生素D3比补充维生素D3更有效达到维生素D充足。
  • 功能障碍脂肪组织中β2-肾上腺素能受体蛋白表达降低。

核心结论

  • 功能障碍性脂肪组织显示儿茶酚胺诱导的维生素D3和25-羟基维生素D3释放减少及维生素D代谢酶活性改变;因此,补充25-羟基维生素D3对肥胖个体更有效。

研究设计与样本

  • 前瞻性研究,招募54名正常体重和67名肥胖男性,随机分配接受每周50微克25-羟基维生素D3或每周150微克维生素D3补充1年,若6个月时未达到维生素D充足(血清25-羟基维生素D3 >50 nmol/L)则剂量增加50%;97名受试者完成研究。

主要发现

  • 在胰岛素抵抗脂肪细胞中,D3和25-羟基维生素D3的摄取更高,但肾上腺素刺激后,对照组细胞中D3和25-羟基维生素D3的减少更强,且对照组细胞Cyp27a1和Cyp27b1表达增加、25-羟基维生素D3水平更高。
  • 肥胖受试者皮下脂肪组织中肾上腺素诱导的D3和25-羟基维生素D3释放减弱;在胰岛素抵抗细胞和肥胖皮下脂肪组织中,β2-肾上腺素能受体蛋白表达均降低。
  • 补充25-羟基维生素D3在肥胖受试者中更有效达到维生素D充足,但在正常体重受试者中未显示更有效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Vitamin D accumulates in adipose tissue (AT), and vitamin D deficiency is frequent in obesity. OBJECTIVE: We hypothesize that trafficking of vitamin D is altered in dysfunctional AT. DESIGN, PATIENTS, SETTINGS: Fifty-four normal-weight and 67 obese males were recruited in a prospective study and randomly assigned to supplementation with 50 µg/wk 25-hydroxyvitamin-D3 or 150 µg/wk vitamin D3 for 1 year, raising dosage by 50% if vitamin D sufficiency [serum 25-hydroxyvitamin-D3 >50 nmol/L], was not achieved at 6 months; 97 subjects completed the study. METHODS: Vitamin D3 and 25-hydroxyvitamin-D3 were quantified by HPLC-MS in control and insulin-resistant (IR) 3T3-L1 cells and subcutaneous AT (SAT) from lean and obese subjects, incubated with or without adrenaline; expression of 25-hydroxylase (Cyp27a1), 1α-hydroxylase (Cyp27b1), and vitamin D receptor (Vdr) was analyzed by real-time polymerase chain reaction. RESULTS: In IR adipocytes, uptake of D3 and 25-hydroxyvitamin-D3 was higher, but, after adrenaline stimulation, the decrement in D3 and 25-hydroxyvitamin-D3 was stronger in control cells, which also showed increased expression of Cyp27a1 and Cyp27b1 and higher levels of 25-hydroxyvitamin-D3. In SAT from obese subjects, adrenaline-induced release of D3 and 25-hydroxyvitamin-D3 was blunted; in both IR cells and obese SAT, protein expression of β2-adrenergic receptor was reduced. Supplementation with 25-hydroxyvitamin-D3 was more effective in achieving vitamin D sufficiency in obese, but not in normal weight subjects. CONCLUSION: Dysfunctional AT shows a reduced catecholamine-induced release of D3 and 25-hydroxyvitamin-D3 and altered activity of vitamin D-metabolizing enzymes; for these reasons supplementation with 25-hydroxyvitamin-D3 is more effective in obese individuals.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Di Nisio A, De Toni L, Sabovic I, et al. Impaired Release of Vitamin D in Dysfunctional Adipose Tissue: New Cues on Vitamin D Supplementation in Obesity. J Clin Endocrinol Metab. 2017. PMID: 28187222. doi:10.1210/jc.2016-3591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。